Dr. Scott Antonia is the Director, Center for Cancer Immunotherapy at Duke Cancer Institute, and Professor of Medicine at Duke University, where he is a lung cancer physician. He leads Center for Cancer Immunotherapy of Duke Cancer Institute to look for cancer immunotherapy discoveries that show promise in any cancer types. He works with the original investigator to accelerate the finding into a drug that can be tested in a clinical trial. The team members help accomplish all the tasks required to take a finding to human trials, from conducting additional lab studies, to designing a clinical trial, and even manufacturing a drug. Prio to joining Duke University, he was at Moffitt Cancer Center developing immunotherapies to fight lung cancer, including one that in June 2019 changed the standard of care for stage III non-small-cell lung cancer. He completed Medical Oncology Fellowship and Internal Medicine Residency at Yale University School of Medicine. He received M.D., Ph.D. at University of Connecticut School of Medicine.